Department of Pharmacy, Zhongshan Hospital (Xiamen), Fudan University, Fujian Xiamen, China.
Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241254107. doi: 10.1177/10760296241254107.
Ticagrelor is an antiplatelet drug, and its use increases the risk of bleeding. Coronary artery disease is significantly influenced by the widespread occurrence of diabetes mellitus. In order to decrease the incidence of clinical adverse events, a novel bleeding and thrombosis score is developed in this research.
We conducted a retrospective analysis of patient data from two medical centers who were diagnosed with diabetes mellitus and treated with ticagrelor. We gathered information on every patient from the electronic database of the hospital and follow-up. The collected data were statistically analyzed to obtain risk factors for bleeding and ischemic events.
A total of 851 patients with diabetes mellitus who have been administered ticagrelor are included in our investigation. A total of 76 patients have bleeding events and 80 patients have ischemic events. The analysis of multiple variables indicates that characteristics like the age of >65, having a previous occurrence of bleeding, experiencing anemia, using aspirin, and taking atorvastatin are linked to a higher likelihood of bleeding. Additionally, the age of >65, smoking, having a history of blood clots, and having a BMI ≥ 30 are found to increase the risk of ischemia.
The AB score established in this study was better than the HAS-BLED score，and the same is true for the ABST score to the CHADS-VASc score. This new risk assessment model can potentially detect patients who are at high risk for bleeding and ischemic events. For high-risk patients, the dose of ticagrelor can be adjusted appropriately or the medication can be adjusted.(2023-09-11, ChiCTR2300075627).
替格瑞洛是一种抗血小板药物，其使用会增加出血风险。冠心病受糖尿病广泛发生的显著影响。为降低临床不良事件的发生率，本研究开发了一种新的出血和血栓形成评分。
我们对两家医疗中心诊断为糖尿病并接受替格瑞洛治疗的患者数据进行了回顾性分析。我们从医院的电子数据库和随访中收集每位患者的信息。对收集到的数据进行统计学分析，以获得出血和缺血事件的风险因素。
本研究共纳入 851 例接受替格瑞洛治疗的糖尿病患者。共有 76 例患者发生出血事件，80 例患者发生缺血事件。多变量分析表明，年龄>65 岁、有既往出血史、贫血、使用阿司匹林和阿托伐他汀等特征与出血风险增加相关。此外，年龄>65 岁、吸烟、有血栓史和 BMI≥30 与缺血风险增加相关。
本研究建立的 AB 评分优于 HAS-BLED 评分，ABST 评分优于 CHADS-VASc 评分。这种新的风险评估模型有可能检测出出血和缺血事件风险较高的患者。对于高危患者，可以适当调整替格瑞洛的剂量或调整药物。（2023-09-11，ChiCTR2300075627）。
